CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Vlad Coric

Chairman and Chief Executive Officer, Biohaven

Search every verified Vlad Coric interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Vlad Coric, Chairman and Chief Executive Officer of Biohaven, has recently discussed the company's pipeline across multiple therapeutic areas, including precision immunology, obesity, and epilepsy. In a January 2026 appearance on CNBC's Mad Money, he described the company's degrader technology, exclusively licensed from Yale University, as targeting disease-causing antibodies in the blood without suppressing the broader immune system, citing first-ever human data in IgA nephropathy as a validation of the platform. He also stated that the company's approach to epilepsy aims to offer treatments without the side-effect burden of existing therapies. In earlier appearances, Coric discussed Biohaven's experimental obesity drug, taldefgrobep alfa, a myostatin inhibitor designed to achieve weight loss while preserving muscle mass, contrasting it with GLP-1 treatments that he said are associated with muscle loss. He has also spoken about the company's work in Parkinson's disease, focusing on modulating the immune system's response to alpha-synuclein plaques, and in Alzheimer's disease through glutamate modulation. Coric has emphasized the company's commitment to addressing unmet patient needs, stating that "patients can't wait" and that research is conducted as if family members were affected by the diseases being studied.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →